MTHFR & Methylation Protocol Guide — Complete FM Practitioner Reference

The complete clinical reference for FM practitioners — from genotype interpretation to homocysteine optimization, supplement protocols, B12 forms, dosing, and monitoring.

Bookmark this page. If you see MTHFR results in your practice — and you will — this is the guide you'll return to.

MTHFR (methylenetetrahydrofolate reductase) is one of the most commonly ordered genetic tests in functional medicine, and one of the most consistently mismanaged. The issue isn't complexity — the biochemistry is learnable. The issue is that conventional medicine hasn't caught up, so patients arrive with elevated homocysteine, folic acid prescriptions that aren't helping, and no protocol. This guide closes that gap.

---

Table of Contents

1. What MTHFR Actually Does — The Biochemistry in Plain Terms
2. MTHFR Variants: C677T vs A1298C — Clinical Differences That Matter
3. Why Folic Acid Fails MTHFR Patients (and What to Use Instead)
4. The Complete Methylation Protocol Stack
5. B12 in MTHFR: Form, Testing, and Dosing
6. Dosing Methylfolate: The Start-Low-Titrate-Slow Rule
7. Monitoring: Homocysteine as the Functional Readout
8. When Protocols Fail: Troubleshooting Persistent High Homocysteine
9. MTHFR and Associated Conditions: Cardiovascular Risk, Pregnancy, Psychiatric
10. FAQ

---

1. What MTHFR Actually Does — The Biochemistry in Plain Terms

The one-sentence version: MTHFR converts dietary folate into the biologically active form your cells can actually use — and when the enzyme is impaired, the entire methylation cycle runs at a deficit.

MTHFR encodes the enzyme methylenetetrahydrofolate reductase, which performs one specific conversion: 5,10-methylenetetrahydrofolate → 5-methyltetrahydrofolate (5-MTHF). That product — also called methylfolate or L-methylfolate — is the active form of folate that donates a methyl group to methionine synthase, converting homocysteine back to methionine. Methionine then becomes S-adenosylmethionine (SAMe), the universal methyl donor used across hundreds of downstream reactions:

• DNA methylation — gene expression regulation, epigenetic control, cancer suppression
• Neurotransmitter synthesis — serotonin, dopamine, norepinephrine require methylation steps
• Phase 2 detoxification — catechol methylation, estrogen deactivation via COMT
• Glutathione regeneration — via the transsulfuration pathway (homocysteine → cysteine → glutathione)
• Myelin synthesis — critical for neurological integrity

When MTHFR activity is reduced, all of these downstream processes operate at a deficit. Homocysteine accumulates because it cannot be efficiently remethylated. SAMe production drops. The methylation cycle slows across the board.

This is why the clinical picture of MTHFR dysfunction is so broad: fatigue, cognitive fog, mood instability, cardiovascular risk, poor detoxification, impaired glutathione production. These aren't MTHFR-specific symptoms in the traditional diagnostic sense — they're the symptoms of widespread methylation insufficiency. That breadth is the point.

Figure 1. The methylation cycle — where each supplement in the protocol enters and why.

---

2. MTHFR Variants: C677T vs A1298C — Clinical Differences That Matter

There are two clinically relevant MTHFR variants. They are not interchangeable, and treating them as equivalent is one of the most common errors in MTHFR management.

Figure 2. C677T vs A1298C — clinical differences that change your protocol.

C677T: The Thermolabile Variant

C677T is a cytosine-to-thymine substitution at position 677 in exon 4. It produces a thermolabile enzyme with significantly reduced activity — the more copies, the worse the impairment.

Genotype	Enzyme Activity	Prevalence (Caucasian)
CC (wild type)	100%	~50%
CT (heterozygous)	~65%	~35%
TT (homozygous)	~25–30%	~10–15%

The TT homozygous is the most clinically significant genotype. A patient with C677T TT is operating at approximately 25% of normal MTHFR enzyme capacity. This is not a mild variant — it's a 75% reduction in the key enzymatic conversion that drives the methylation cycle. Elevated homocysteine is the expected finding, not a coincidental one.

Key C677T clinical features:

• Elevated homocysteine is the hallmark and the primary biomarker to track
• Riboflavin (B2) is a critical and genotype-specific cofactor. The C677T enzyme is thermolabile because it has reduced FAD (flavin adenine dinucleotide) binding affinity. Riboflavin is the FAD precursor — supplementing it stabilizes the enzyme and partially restores function. McNulty et al. (Circulation, 2006; PMID 16380544) demonstrated this mechanism specifically in C677T carriers. This finding does not apply to A1298C. Riboflavin is one of the most commonly omitted components of MTHFR protocols and one of the highest-yield additions for C677T patients.
• Responds well to the standard methylation protocol (methylfolate + methylcobalamin + P5P + riboflavin)

A1298C: Different Mechanism, Different Clinical Profile

A1298C is an adenine-to-cytosine substitution at position 1298 in exon 7. It reduces MTHFR activity less dramatically than C677T.

Genotype	Enzyme Activity	Clinical Weight
AA (wild type)	100%	—
AC (heterozygous)	~80–85%	Mild; often subclinical alone
CC (homozygous)	~60–70%	Moderate; clinically relevant

A1298C practical notes:

• A1298C homozygous is clinically meaningful but less impactful than C677T homozygous
• Homocysteine is less consistently elevated with A1298C — but it should still be checked, not assumed normal
• A1298C affects BH4 (tetrahydrobiopterin) production, which matters for neurotransmitter synthesis (dopamine, serotonin). Practitioners frequently observe more neuro/psychiatric symptom burden in A1298C patients relative to their homocysteine levels
• Riboflavin is NOT indicated for A1298C — this is a critical protocol difference that many practitioners miss

Compound Heterozygous: One Copy of Each

A patient with CT at 677 and AC at 1298 — one copy of each variant — carries a compound heterozygous genotype. This is functionally equivalent to moderate-to-severe methylation impairment and should be treated as clinically significant. These patients typically have elevated homocysteine and a fuller symptom burden than either variant alone would predict.

The key clinical message: Do not report MTHFR results as simply "positive" or "negative." C677T TT homozygous, A1298C CC homozygous, and compound heterozygous are distinct clinical scenarios with different protocols, different cofactor priorities, and different expected treatment responses.

Full clinical protocol with titration ladder and case example: MTHFR C677T Homozygous Treatment Protocol

---

3. Why Folic Acid Fails MTHFR Patients (and What to Use Instead)

This is the most important clinical insight in this entire guide — and the most commonly violated. Patients arrive with elevated homocysteine, a methylated supplement is indicated, and they've been prescribed folic acid or are taking a standard prenatal loaded with it. That needs to stop.

The Core Problem: You're Asking a Broken Enzyme to Do All the Work

Folic acid, the synthetic oxidized form of folate used in supplements and fortified foods, must undergo multi-step enzymatic conversion before it can enter the methylation cycle:

Folic acid → DHFR → Dihydrofolate → DHFR → Tetrahydrofolate → MTHFR → 5-MTHF
                                                                 ^^^
                                                          The broken step

In a C677T TT patient with 25% MTHFR activity, you are routing 100% of the folate supply through an enzyme that is 75% impaired. The result: functional folate deficiency despite adequate or even elevated serum folate.

A patient can present with serum folate at 20 ng/mL — technically "normal" — while running the methylation cycle on a significant deficit. Standard serum folate tests do not distinguish between active 5-MTHF and unmetabolized folic acid. They measure total folate. That number tells you almost nothing about functional methylation status.

Unmetabolized Folic Acid (UMFA): Beyond Just Not Helping

The problem isn't only that folic acid doesn't adequately support methylation in MTHFR patients. It may actively interfere.

When folic acid intake exceeds DHFR conversion capacity, it circulates as unmetabolized folic acid (UMFA) — a synthetic compound that performs none of the functions of active folate. Evidence suggests UMFA may:

• Competitively inhibit DHFR, compounding the conversion bottleneck
• Impair natural killer (NK) cell cytotoxicity — a finding associated with high folic acid intake in postmenopausal women (Troen et al., J Nutr, 2006; PMID 16365081)

MTHFR patients on folic acid supplements plus fortified foods — cereals, white flour, standard prenatals — represent the highest UMFA accumulation risk. They often have the highest folic acid intake and the lowest conversion capacity simultaneously. This is exactly backwards from what they need.

The Solution: L-Methylfolate (5-MTHF)

L-methylfolate (5-methyltetrahydrofolate, 5-MTHF) is the bioidentical, biologically active form of folate. It requires no MTHFR conversion. It enters the methylation cycle directly — bypassing the enzyme block entirely.

• No DHFR or MTHFR conversion required
• No UMFA accumulation
• Directly supports homocysteine remethylation via methionine synthase
• Clinically superior to folic acid for homocysteine reduction in MTHFR patients (PMID 38892484)

The rule is simple: if the MTHFR variant is confirmed, folic acid is out. L-methylfolate is in.

Look for Quatrefolic® (glucosamine salt of 5-MTHF) or Metafolin® (calcium salt of 5-MTHF) — these are the stabilized, commercially validated forms used in clinical research. Generic "methylfolate" products vary in stability and bioavailability.

A Note on Folinic Acid

For patients who cannot tolerate methylfolate — particularly those with COMT variants or an over-methylation phenotype who experience anxiety, insomnia, or irritability on 5-MTHF — folinic acid (5-formyl-THF, leucovorin) is a viable middle path. Folinic acid is an active folate form that does not directly donate a methyl group, making it metabolically gentler. It still bypasses the MTHFR block. This is not a first-line recommendation, but it's an important clinical tool for the ~10–15% of patients who react to methylfolate.

Full mechanism breakdown with dosing and case example: Methylfolate vs Folic Acid: What MTHFR Patients Need

---

4. The Complete Methylation Protocol Stack

Methylfolate is the anchor. But methylation is not a single-enzyme process — it's a cycle with multiple cofactor requirements at every step. Getting the full stack right is what separates a partial laboratory response from a complete clinical resolution.

Figure 3. The complete methylation protocol — why each component earns its place.

Core Protocol

Supplement	Preferred Form	Starting Dose	Clinical Role
L-Methylfolate	5-MTHF (Quatrefolic® or Metafolin®)	400–800 mcg/day	Direct methyl donor; bypasses MTHFR block
B12	Methylcobalamin or hydroxycobalamin	1,000 mcg sublingual/day	Methionine synthase cofactor; closes the remethylation cycle
B6	Pyridoxal-5'-phosphate (P5P)	25–50 mg/day	Transsulfuration pathway: homocysteine → cysteine → glutathione
B2 (Riboflavin)	Riboflavin 5'-phosphate	100–200 mg/day	MTHFR enzyme stabilization — C677T specific; often omitted
Magnesium	Glycinate or malate	200–400 mg/day	Cofactor for methyltransferases; near-universally depleted

Why Each Component Earns Its Place

L-Methylfolate is the direct bypass. Every other intervention in this protocol supports the methylation cycle — but 5-MTHF is the only form of folate that actually feeds it without requiring MTHFR conversion. This is the non-negotiable core.

Methylcobalamin (B12) is a co-lead, not a supporting actor. The methionine synthase reaction that remethylates homocysteine back to methionine requires methylcobalamin as a direct cofactor. Without adequate functional B12, methylfolate alone cannot normalize homocysteine — it donates a methyl group to a reaction that still can't complete. Get the B12 wrong (wrong form, inadequate dose, poor absorption) and the protocol will underperform regardless of how well everything else is optimized.

P5P (Pyridoxal-5'-phosphate) supports the disposal route. When homocysteine can't be remethylated fast enough, it needs an alternative exit: the transsulfuration pathway. B6 in its active P5P form is the required cofactor for homocysteine → cystathionine → cysteine → glutathione. This pathway is also the reason MTHFR patients tend toward glutathione insufficiency — impair both remethylation and transsulfuration and you're blocking two routes simultaneously. Avoid standard pyridoxine hydrochloride; P5P is the active form that doesn't require hepatic conversion.

Riboflavin (B2) is the most commonly omitted and highest-yield addition for C677T patients specifically. The C677T thermolabile enzyme has reduced FAD (flavin adenine dinucleotide) binding affinity — riboflavin is the FAD precursor. McNulty et al. showed that riboflavin supplementation stabilizes the C677T enzyme and reduces homocysteine independently of methylfolate by up to 22% in TT homozygotes (PMID 16380544). This is not a general supplement recommendation — it is a genotype-specific intervention. If the patient is C677T and riboflavin is not in the protocol, the protocol is incomplete.

Magnesium is required as a cofactor for over 300 enzymatic reactions including multiple methyltransferases. Magnesium deficiency is near-universal in functional medicine patients — dietary insufficiency, chronic stress depletion, and GI dysfunction compound across most of our patient population. It is one of the most consistent reasons a methylation protocol stalls before you've added any new agents. Address it before assuming failure.

Adjunctive Additions (When Core Protocol Is Insufficient)

For patients with persistently elevated homocysteine despite the complete core stack:

• TMG (trimethylglycine / betaine): Remethylates homocysteine via the BHMT pathway — an MTHFR-independent bypass. Particularly useful when the primary MTHFR pathway is severely compromised. Dose: 500–1,500 mg/day. Well-tolerated and often meaningfully moves the needle in resistant cases. (PMID 19855400)
• Zinc: Cofactor for methionine synthase. Frequently depleted in the FM patient population and easy to add.
• SAMe: Reserve for patients with documented deficiency or specific psychiatric indications (treatment-resistant depression with low methylation markers). SAMe bypasses the whole cycle by supplying the methyl donor directly. Use cautiously — it can drive over-methylation symptoms in sensitive patients, particularly those with COMT variants.

Full B12 form comparison, functional testing, and dosing by route: MTHFR and B12: Methylcobalamin Protocols

---

5. B12 in MTHFR: Form, Testing, and Dosing

Why B12 form matters more than dose. A patient can be taking 5,000 mcg of cyanocobalamin daily and have functional B12 insufficiency at the tissue level. Form determines usability. Dose is secondary.

The Right Form

B12 Form	Conversion Required	Recommendation
Cyanocobalamin	Multi-step hepatic conversion; releases cyanide moiety	❌ Avoid in MTHFR patients
Methylcobalamin	None — directly usable	✅ First choice
Hydroxycobalamin	Converts endogenously to methyl- and adenosylcobalamin	✅ Excellent alternative
Adenosylcobalamin	None — mitochondrial form	Adjunctive (energy metabolism)

Cyanocobalamin is the synthetic form found in most standard supplements, fortified foods, and hospital formulations. It requires multi-step hepatic conversion to become active — an unnecessary burden in patients with already-impaired methylation. It also releases a cyanide moiety upon conversion, a clinically minor but relevant concern in patients with depleted glutathione.

Use methylcobalamin first. Switch to hydroxycobalamin if the patient has concurrent COMT variants or an over-methylation phenotype (anxiety, insomnia, palpitations on methylcobalamin). Hydroxycobalamin is well-tolerated even in methylation-sensitive patients.

Why Serum B12 Misses Functional Deficiency

Serum B12 measures total cobalamin, including inactive analogues that don't participate in methylation. A patient with serum B12 of 600 pg/mL can have functional B12 deficiency at the tissue level. This isn't a lab error — it's the wrong test.

The functional B12 panel:

Test	What It Shows	Functional Target
Serum B12	Total — unreliable alone	Baseline reference only
MMA (methylmalonic acid)	Adenosylcobalamin deficiency at mitochondrial level	< 0.27 μmol/L
Homocysteine	Methylcobalamin-dependent remethylation status	< 8 μmol/L
Holotranscobalamin (holoTC)	Active B12 fraction — most specific marker	> 35 pmol/L

Clinical pearl: When homocysteine stays elevated despite methylfolate optimization, the next question is always whether there's a functional B12 deficit. Check MMA and reassess B12 form and route before adding more methylfolate. More methylfolate does not compensate for inadequate B12 — they're cofactors in the same reaction.

Dosing by Route

Oral B12 absorption is intrinsic-factor dependent — unreliable in patients with hypochlorhydria, PPI use, H. pylori history, or autoimmune gastritis. All common in functional medicine practice. Sublingual delivery bypasses this via buccal absorption and is the preferred first-line route.

Route	Standard Dose	Clinical Indication
Sublingual methylcobalamin	1,000–2,000 mcg/day	First-line in FM practice
Oral tablet (swallowed)	1,000–5,000 mcg/day	If sublingual unavailable; less reliable
IM hydroxycobalamin	1,000 mcg/week × 8 weeks (loading)	Documented absorption failure, severe deficiency, neuropathy

---

6. Dosing Methylfolate: The Start-Low-Titrate-Slow Rule

This is where well-intentioned methylation protocols most commonly fail. High-dose methylfolate prescribed at the first visit, a bad patient experience in week two, and the protocol gets abandoned — along with the patient's trust that the approach can work at all.

The Methylation Start Reaction

Methylfolate is potent. When a patient has had long-standing methylation insufficiency, suddenly providing adequate 5-MTHF can trigger rapid resumption of methylation activity — accelerating neurotransmitter synthesis and methyl cycling. The result is a transient symptom spike that is not dangerous but is reliably uncomfortable if the patient isn't warned.

Methylation start reaction symptoms:

• Anxiety, irritability, racing thoughts
• Insomnia — often the most prominent symptom
• Palpitations
• Headache
• Emotional lability

These resolve as the methylation cycle recalibrates, typically within days to 1–2 weeks. But patients who aren't prepared for this will stop the protocol and tell you it made them feel worse. Counsel them before they start — and specifically tell them that if they feel worse in the first two weeks, the dose may need to be reduced rather than the protocol abandoned.

Titration Ladder

Timeframe	Methylfolate Dose
Weeks 1–2	400 mcg/day
Weeks 3–4	800 mcg/day (if tolerated)
Weeks 6–8	1,000–1,600 mcg/day (based on tolerance and symptom response)
Week 8–12	Retest homocysteine; adjust dose based on lab response

Target maintenance dose: Most patients stabilize at 800–1,600 mcg/day. Some need higher doses — let the lab response guide escalation, not the bottle label or the patient's subjective sense that "more must be better."

If a start reaction occurs: Reduce the dose by 50%. Some practitioners add niacinamide (B3 — the non-flush form, not niacin) transiently at 50–100 mg as a methyl buffer. Niacinamide accepts methyl groups and can rapidly dampen over-methylation symptoms when they're acute. Don't confuse niacinamide with the flushing form of niacin; the dosing and mechanism here are different.

On high-dose methylfolate (>5 mg): This is a separate clinical territory — reserved for documented severe folate deficiency, treatment-resistant depression with confirmed folate insufficiency, or specific psychiatric augmentation protocols. It is not a default escalation step when lower doses haven't normalized homocysteine. If the protocol isn't working at 1,600 mcg/day, the troubleshooting checklist in Section 8 is more likely to solve the problem than increasing dose.

---

7. Monitoring: Homocysteine as the Functional Readout

The Right Marker to Track

The MTHFR genotype doesn't change. Retesting it over time is pointless. What changes — and what tells you whether the methylation cycle is actually working — is homocysteine. This is your primary clinical tracking biomarker.

Elevated homocysteine (above functional target) is the downstream signature of impaired methylation. It reflects everything upstream: inadequate methylfolate, insufficient functional B12, depleted cofactors, unresolved absorption issues. When you optimize the methylation protocol correctly, homocysteine falls. That's your success metric.

Target Values

Marker	Conventional Lab Reference	Functional Target
Homocysteine	< 10–12 μmol/L	< 8 μmol/L
RBC folate	280–791 ng/mL	> 400 ng/mL
B12 (serum)	> 200 pg/mL	> 500 pg/mL
MMA	< 0.4 μmol/L	< 0.27 μmol/L

The conventional homocysteine upper limit of 10–12 μmol/L is too permissive from a functional standpoint. A patient who drops from 14 to 10.8 μmol/L has improved — but the protocol is not finished. The target is below 8 μmol/L.

Use RBC folate, not serum folate. Serum folate measures the most recent intake and is easily transiently elevated after a single folate-rich meal. RBC folate reflects intracellular folate stores over the prior 3 months — a much more meaningful indicator of functional folate status. Serum folate can be falsely reassuring in MTHFR patients for exactly the reasons discussed in Section 3.

When to Retest

Retest at 8–12 weeks after initiating the protocol. This is the window in which most homocysteine response occurs, based on RCT data (PMID 38892484). Testing at 4 weeks is premature and frequently misleads practitioners into concluding the protocol isn't working when it simply hasn't had enough time. Announce the retest timeline at the time of protocol initiation so the patient understands what to expect.

Once the target is reached and confirmed on a stable protocol, annual monitoring is appropriate for most patients.

Baseline and Monitoring Panel

At baseline and at 8–12-week recheck:

• Homocysteine (primary tracking marker)
• RBC folate (intracellular stores; not serum folate)
• B12 serum (baseline; upgrade to MMA if response is suboptimal)
• MMA (whenever functional B12 status is in question or protocol response is poor)
• Optional: holotranscobalamin (most specific active B12 marker; underutilized in practice)

---

8. When Protocols Fail: Troubleshooting Persistent High Homocysteine

When homocysteine remains elevated after 8–12 weeks on the methylation stack, work through this checklist before escalating doses or adding agents. Most protocol failures have identifiable, correctable causes.

The Troubleshooting Checklist

1. Wrong B12 form — check the label

The single most common cause of protocol failure. Is the patient actually taking methylcobalamin or hydroxycobalamin? Most commercial B-complex supplements, standard prenatals, and OTC multivitamins contain cyanocobalamin. Patients frequently believe they've "switched to B12" without understanding that form determines function. Ask them to photograph the label. This is the first question — not the last resort.

2. Riboflavin omitted in C677T patients

If the genotype is C677T and riboflavin is not in the protocol, this is a likely major contributor to the partial response. Add riboflavin 5'-phosphate 100–200 mg/day and retest at 6–8 weeks. For C677T TT homozygotes in particular, riboflavin alone has been shown to reduce homocysteine by up to 22% (PMID 16380544). It's not a minor addition.

3. Patient is still consuming significant folic acid

Hidden folic acid accumulates from fortified cereals, white flour products, standard prenatals, and OTC multivitamins. UMFA from ongoing folic acid intake actively competes with and interferes with the methylation cycle (see Section 3). Review the patient's complete supplement list and dietary pattern. Eliminating fortified grain consumption can produce a meaningful homocysteine improvement independent of anything you're prescribing.

4. Magnesium insufficiency not addressed

Magnesium depletion is near-universal in FM patients and rarely supplemented at adequate doses. Most patients who need 300–400 mg/day are getting far less. Before escalating methylfolate or adding new agents, confirm magnesium is addressed adequately. This is one of the most consistent reasons protocols stall.

5. Gut absorption impairment

Oral supplementation may be functionally inadequate in patients with significant GI pathology: hypochlorhydria, SIBO, IBD, or significant mucosal compromise. These patients may require sublingual or injectable B12 (IM hydroxycobalamin loading) and liposomal or sublingual methylfolate formulations. If the patient has gut issues and the protocol isn't moving, route is the likely variable.

6. MTR/MTRR co-polymorphisms

MTR (methionine synthase) and MTRR (methionine synthase reductase) polymorphisms compound B12 demand and can cause protocol failure even with excellent MTHFR management. If genotyping was limited to MTHFR only, consider an expanded methylation panel (MTR, MTRR, COMT) in treatment-resistant cases. These variants increase B12 turnover and can require meaningfully higher doses or IM delivery. (PMID 38056998)

7. High SAMe demand from downstream consumers

Chronic psychological stress, high estrogen burden, and concurrent COMT or CBS variants all increase the rate at which SAMe is consumed — effectively creating a methylation demand that outpaces supply even with an optimized protocol. In these cases, direct SAMe supplementation (200–400 mg/day with careful titration) may be necessary. Use cautiously — SAMe can precipitate over-methylation symptoms in sensitive patients, and escalating dose isn't always the answer. Address the downstream demand (stress reduction, estrogen optimization, COMT support) in parallel.

---

9. MTHFR and Associated Conditions: Cardiovascular Risk, Pregnancy, Psychiatric

Cardiovascular Risk

Elevated homocysteine is an independent cardiovascular risk factor. Meta-analyses of prospective cohort studies have found approximately a 25% increase in ischemic heart disease risk and a 59% increase in stroke risk for each 5 μmol/L rise in homocysteine (PMID 25449138). The debate about whether homocysteine is causal versus a marker has continued in the literature — several large intervention trials failed to show CV event reduction from B-vitamin lowering of homocysteine. The functional medicine framing on this is straightforward: we don't wait for the causality debate to resolve when the intervention is low-risk and the metabolic deficit is real.

Practical implication for the FM practitioner: MTHFR C677T TT patients with elevated homocysteine should be considered for early cardiovascular risk stratification — advanced lipid testing (NMR lipoprofile, LDL particle number, sdLDL), inflammatory markers (hs-CRP, Lp-PLA2), and a targeted prevention conversation. The methylation protocol becomes part of the CVD prevention stack, not a standalone "genetics thing."

Pregnancy and Recurrent Pregnancy Loss

MTHFR testing is commonly triggered by recurrent pregnancy loss, neural tube defect history, or fertility workup. The connections are well-established:

• Folate is essential for neural tube closure, which occurs at days 21–28 of embryogenesis — often before a patient knows she's pregnant
• MTHFR-impaired patients on folic acid may have functional folate insufficiency at the embryological level despite normal serum folate
• Elevated homocysteine is associated with adverse pregnancy outcomes including neural tube defects, placental abruption, preeclampsia, and recurrent early loss

Protocol for pregnancy planning or active pregnancy in MTHFR patients:

• Switch prenatal to a methylated formulation — methylfolate + methylcobalamin, not folic acid + cyanocobalamin. Many "premium" prenatals still contain folic acid and cyanocobalamin. Check the label on every prenatal you recommend.
• Optimize homocysteine to < 8 μmol/L before conception if possible. The metabolic environment at conception and implantation matters.
• Add riboflavin 5'-phosphate if C677T genotype — this is consistently omitted from prenatals
• Eliminate fortified grain folic acid sources during the preconception and first trimester window

Important clinical framing: Do not promise pregnancy outcome improvement from homocysteine optimization. We're correcting a documented metabolic deficit and reducing a quantifiable risk factor. We don't guarantee outcomes. Frame this as metabolic optimization and risk reduction — not a fertility treatment.

Psychiatric Presentations

MTHFR variants are over-represented in several psychiatric populations, and the mechanism is coherent: methylation insufficiency impairs serotonin, dopamine, and norepinephrine synthesis; impairs SAMe-dependent catecholamine methylation; and reduces BH4 (particularly in A1298C patients), which is a rate-limiting cofactor for neurotransmitter production.

Depression: Multiple psychiatric trials have evaluated adjunctive L-methylfolate for treatment-resistant depression. The clinical finding — that folate insufficiency correlates with antidepressant non-response, and that methylfolate augmentation improves response — is mechanistically consistent with MTHFR physiology. Standard adjunctive dosing in psychiatric literature is 7.5–15 mg/day of L-methylfolate — significantly higher than the typical FM supplement protocol. This territory requires more careful titration and closer monitoring.

Anxiety: Particularly in compound heterozygous patients with concurrent COMT variants, the over-methylation phenotype — presenting primarily with anxiety, insomnia, and irritability — is a distinct clinical pattern. These patients are not good candidates for high-dose methylfolate. They need slower titration, potentially folinic acid instead of 5-MTHF, and COMT-supportive interventions (magnesium, EGCG, reducing catecholamine load).

ADHD and ASD: The evidence is less conclusive, but methylation support — particularly addressing folate and B12 deficiencies — is a standard component of integrative protocols for these presentations. The BH4-A1298C connection is especially worth exploring in patients with combined attention and mood symptoms.

Clinical pearl for psychiatric MTHFR patients: Always start methylfolate lower and titrate more slowly. The start reaction in psychiatric patients — anxiety, racing thoughts, insomnia — can be amplified relative to the general population and may be mistaken for clinical deterioration or medication interaction. Pre-counsel explicitly that transient worsening is possible in the first 1–2 weeks and establish a clear dose-reduction plan before they start.

---

10. FAQ

Q: Does everyone with an MTHFR mutation need treatment?

A: No. The presence of an MTHFR variant is not itself an indication for treatment. The indication is elevated homocysteine (above functional target of < 8 μmol/L) and/or clinical symptoms consistent with methylation insufficiency. C677T heterozygous carriers with normal homocysteine and no symptoms do not require a supplement protocol. However, they should avoid synthetic folic acid in their supplements and switch to methylated forms in any prenatal — that's a harm reduction step, not a therapeutic intervention.

---

Q: Should I tell patients to stop folic acid from food as well?

A: The target is synthetic folic acid — the form found in fortified foods (breakfast cereals, white flour, standard breads, pasta) and most supplements. These are the hidden UMFA accumulation sources. Natural food folates in dark leafy greens, legumes, and liver are fine and actively beneficial — the issue is synthetic folic acid, not folate broadly. A simple instruction: avoid fortified grain products and read supplement labels for "folic acid." Switching to whole food sources of carbohydrates eliminates the problem at the dietary level.

---

Q: Can I use a methylated B-complex instead of individual supplements?

A: For maintenance, absolutely. Many patients do well long-term on a quality methylated multivitamin or B-complex that contains L-methylfolate, methylcobalamin, P5P, and riboflavin. For active correction of elevated homocysteine — especially during the titration phase — individual supplementation gives you dose control that a multi doesn't. The titration ladder in Section 6 requires dose adjustment. Once homocysteine is at target and stable, transitioning to a methylated B-complex or multivitamin for maintenance is a reasonable and practical approach.

---

Q: What is over-methylation and how do I recognize and manage it?

A: Over-methylation refers to the symptom complex triggered by excess methyl group activity — typically from high-dose methylfolate or methylcobalamin in patients who are methylation-sensitive, often those with concurrent low-activity COMT variants. Symptoms: anxiety, insomnia, irritability, palpitations, headache, emotional lability. It is not dangerous but can be alarming to unprepared patients. Management: reduce methylfolate dose by 50%; add niacinamide (B3 — the non-flush, non-niacin form) at 50–100 mg transiently as a methyl buffer. Niacinamide accepts methyl groups and quickly dampens over-methylation symptoms. Longer term: identify the COMT genotype, consider switching from methylfolate to folinic acid, and titrate more slowly.

---

Q: How often should I retest homocysteine after starting the protocol?

A: Retest at 8–12 weeks. The majority of homocysteine response occurs in this window based on RCT evidence (PMID 38892484). Testing at 4 weeks is premature and frequently leads practitioners to incorrectly conclude the protocol isn't working. Set the expectation at the time of protocol initiation: "We'll check this in about 10 weeks." Once the target (< 8 μmol/L) is confirmed on a stable protocol, annual monitoring is appropriate for most patients.

---

Q: Is MTHFR testing appropriate for all functional medicine patients?

A: No universal recommendation exists. High-yield scenarios for ordering MTHFR genotyping: elevated homocysteine on standard labs, recurrent pregnancy loss or neural tube defect history, family history of early cardiovascular disease, treatment-resistant depression or anxiety, and unexplained fatigue or cognitive fog with otherwise unremarkable workup. Worth noting: if homocysteine is elevated and the clinical approach would be identical regardless of genotype — switch to methylated supplements, titrate, retest — some practitioners skip genotyping and treat empirically. The genotype adds specificity (particularly the riboflavin distinction for C677T) but doesn't change the foundational protocol.

---

Q: What is the difference between methylfolate and folinic acid?

A: Both are active folate forms that bypass folic acid's MTHFR conversion requirement. L-methylfolate (5-MTHF) is the most bioactive form — it directly donates a methyl group to the methionine synthase reaction and is the first-line choice for MTHFR patients. Folinic acid (5-formyl-THF, leucovorin) is an active folate intermediate that does not directly donate a methyl group, making it metabolically gentler. This distinction matters for patients who react to methylfolate — COMT variant carriers, over-methylation-sensitive patients, or anyone with anxiety/insomnia on 5-MTHF. Folinic acid is not superior to methylfolate for most patients; it's the tolerable alternative when methylfolate isn't well-tolerated.

---

Q: My patient is on a methylated prenatal. Is that sufficient?

A: It depends on genotype and baseline homocysteine. Many methylated prenatals contain 400–800 mcg L-methylfolate — appropriate for C677T CT heterozygous patients with mildly elevated or borderline homocysteine. C677T TT homozygous patients, especially with frankly elevated homocysteine, typically need higher doses of methylfolate, explicit riboflavin supplementation (usually absent from prenatals), and confirmed B12 form. Check the prenatal label: if it contains cyanocobalamin, switch to one with methylcobalamin or hydroxycobalamin. Then measure homocysteine. The lab tells you if it's enough — not the bottle.

---

Q: Can MTHFR cause low B12 levels?

A: MTHFR doesn't directly cause B12 deficiency, but the relationship is bidirectional. B12 insufficiency impairs the methionine synthase reaction regardless of methylfolate status — and patients with MTHFR variants who are also B12 insufficient have a compounding deficit: both the methyl donor (5-MTHF) and the cofactor (methylcobalamin) for the same reaction are inadequate. Additionally, a "methyl trap" phenomenon can occur in B12 deficiency where folate becomes trapped as 5-MTHF, unable to complete the reaction and cycle back — producing functional folate deficiency even with adequate intake. This is why B12 status must be evaluated in every MTHFR patient, not assumed.

---

Clinical Summary: What to Do Monday Morning

If you're seeing a patient with an MTHFR result in their records, here's the clinical fast path:

1. Check homocysteine if not already done. This is the functional readout. The genotype is context; homocysteine is the action trigger.
2. Identify the variant. C677T TT → add riboflavin to the protocol. A1298C or compound heterozygous → skip riboflavin, focus on methylfolate + methylcobalamin + P5P.
3. Audit what they're currently taking. Folic acid in any form → remove it. Cyanocobalamin → replace it.
4. Start the core stack. L-methylfolate 400 mcg/day to start. Methylcobalamin 1,000 mcg sublingual. P5P 25–50 mg. Riboflavin (if C677T) 100–200 mg. Magnesium glycinate 300–400 mg.
5. Counsel on start reaction. First two weeks may feel worse before better. Reduce dose if needed — don't stop the protocol.
6. Retest at 8–12 weeks. Homocysteine and RBC folate at minimum. Adjust based on response.
7. Target < 8 μmol/L homocysteine. Don't accept "normal" by conventional reference range. That's not the finish line.

---

Additional Resources

• MTHFR C677T Homozygous Treatment Protocol — Full clinical protocol with case example and titration ladder for the most common high-severity genotype
• Methylfolate vs Folic Acid: What MTHFR Patients Need — Mechanism breakdown, UMFA science, supplement selection guide, and case example
• MTHFR and B12: Methylcobalamin Protocols — B12 forms compared, functional B12 testing with MMA and holotranscobalamin, dosing by route
• → Lab Interpretation Hub — The full library of FM lab interpretation guides
• DUTCH Hormone Test Interpretation Guide — COMT variants and methylation overlap in estrogen metabolism

---

Tracking MTHFR protocols across multiple patients — baseline homocysteine, supplement titration timelines, B12 form switches, 8-week rechecks, genotype-specific cofactor adjustments — is exactly the kind of longitudinal complexity that gets lost in generic EMR notes.

See how HANS keeps functional medicine methylation protocols organized across every visit → View HANS Pricing & Plans

---

Citations: PMID 38892484, PMID 38056998, PMID 25449138, PMID 16380544, PMID 16365081, PMID 19855400